Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 301 to 306 of 306 entries
Sorted by: Best Match Show Resources per page
DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model.

Cancers

Lebecque B, Bourgne C, Vidal V, Berger MG.
PMID: 34298798
Cancers (Basel). 2021 Jul 17;13(14). doi: 10.3390/cancers13143587.

Chronic Myeloid Leukemia (CML) is a model to investigate the impact of tumor intra-clonal heterogeneity in personalized medicine. Indeed, tyrosine kinase inhibitors (TKIs) target the BCR-ABL fusion protein, which is considered the major CML driver. TKI use has highlighted...

Cite
Lebecque B, Bourgne C, Vidal V, et al. DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model. Cancers (Basel). 2021;13(14)doi: 10.3390/cancers13143587.
Lebecque, B., Bourgne, C., Vidal, V., & Berger, M. G. (2021). DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model. Cancers, 13(14), . https://doi.org/10.3390/cancers13143587
Lebecque, Benjamin, et al. "DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model." Cancers vol. 13,14 (2021). doi: https://doi.org/10.3390/cancers13143587
Lebecque B, Bourgne C, Vidal V, Berger MG. DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model. Cancers (Basel). 2021 Jul 17;13(14). doi: 10.3390/cancers13143587. PMID: 34298798; PMCID: PMC8307727.
Copy Download .nbib Format: NLM
Ticagrelor added to methotrexate improves rheumatoid arthritis disease severity.

Rheumatology (Oxford, England)

Garshick MS, Rosenthal PB, Luttrell-Williams E, Cronstein BN, Berger JS.
PMID: 34142122
Rheumatology (Oxford). 2021 Nov 03;60(11):5473-5475. doi: 10.1093/rheumatology/keab481.

No abstract available.

Cite
Garshick MS, Rosenthal PB, Luttrell-Williams E, et al. Ticagrelor added to methotrexate improves rheumatoid arthritis disease severity. Rheumatology (Oxford). 2021;60(11):5473-5475doi: 10.1093/rheumatology/keab481.
Garshick, M. S., Rosenthal, P. B., Luttrell-Williams, E., Cronstein, B. N., & Berger, J. S. (2021). Ticagrelor added to methotrexate improves rheumatoid arthritis disease severity. Rheumatology (Oxford, England), 60(11), 5473-5475. https://doi.org/10.1093/rheumatology/keab481
Garshick, Michael S, et al. "Ticagrelor added to methotrexate improves rheumatoid arthritis disease severity." Rheumatology (Oxford, England) vol. 60,11 (2021): 5473-5475. doi: https://doi.org/10.1093/rheumatology/keab481
Garshick MS, Rosenthal PB, Luttrell-Williams E, Cronstein BN, Berger JS. Ticagrelor added to methotrexate improves rheumatoid arthritis disease severity. Rheumatology (Oxford). 2021 Nov 03;60(11):5473-5475. doi: 10.1093/rheumatology/keab481. PMID: 34142122.
Copy Download .nbib Format: NLM
Discovery of a tsunami deposit from the Bronze Age Santorini eruption at Malia (Crete): impact, chronology, extension.

Scientific reports

Lespez L, Lescure S, Saulnier-Copard S, Glais A, Berger JF, Lavigne F, Pearson C, Virmoux C, Müller Celka S, Pomadère M.
PMID: 34326405
Sci Rep. 2021 Jul 29;11(1):15487. doi: 10.1038/s41598-021-94859-1.

A geomorphological survey immediately west of the Minoan town of Malia (Crete) shows that a tsunami resulting from the Bronze Age Santorini eruption reached the outskirts of the Palatial center. Sediment cores testify a unique erosional event during the...

Cite
Lespez L, Lescure S, Saulnier-Copard S, et al. Discovery of a tsunami deposit from the Bronze Age Santorini eruption at Malia (Crete): impact, chronology, extension. Sci Rep. 2021;11(1):15487doi: 10.1038/s41598-021-94859-1.
Lespez, L., Lescure, S., Saulnier-Copard, S., Glais, A., Berger, J. F., Lavigne, F., Pearson, C., Virmoux, C., Müller Celka, S., & Pomadère, M. (2021). Discovery of a tsunami deposit from the Bronze Age Santorini eruption at Malia (Crete): impact, chronology, extension. Scientific reports, 11(1), 15487. https://doi.org/10.1038/s41598-021-94859-1
Lespez, Laurent, et al. "Discovery of a tsunami deposit from the Bronze Age Santorini eruption at Malia (Crete): impact, chronology, extension." Scientific reports vol. 11,1 (2021): 15487. doi: https://doi.org/10.1038/s41598-021-94859-1
Lespez L, Lescure S, Saulnier-Copard S, Glais A, Berger JF, Lavigne F, Pearson C, Virmoux C, Müller Celka S, Pomadère M. Discovery of a tsunami deposit from the Bronze Age Santorini eruption at Malia (Crete): impact, chronology, extension. Sci Rep. 2021 Jul 29;11(1):15487. doi: 10.1038/s41598-021-94859-1. PMID: 34326405; PMCID: PMC8322394.
Copy Download .nbib Format: NLM
Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial.

JAMA cardiology

White HD, O'Brien SM, Alexander KP, Boden WE, Bangalore S, Li J, Manjunath CN, Lopez-Sendon JL, Peteiro J, Gosselin G, Berger JS, Maggioni AP, Reynolds HR, Hochman JS, Maron DJ.
PMID: 33938917
JAMA Cardiol. 2021 Sep 01;6(9):1023-1031. doi: 10.1001/jamacardio.2021.1651.

IMPORTANCE: Traditional time-to-event analyses rate events occurring early as more important than later events, even if later events are more severe, eg, death. Days alive out of hospital (DAOH) adds a patient-focused perspective beyond trial end points.OBJECTIVE: To compare...

Cite
White HD, O'Brien SM, Alexander KP, et al. Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. JAMA Cardiol. 2021;6(9):1023-1031doi: 10.1001/jamacardio.2021.1651.
White, H. D., O'Brien, S. M., Alexander, K. P., Boden, W. E., Bangalore, S., Li, J., Manjunath, C. N., Lopez-Sendon, J. L., Peteiro, J., Gosselin, G., Berger, J. S., Maggioni, A. P., Reynolds, H. R., Hochman, J. S., & Maron, D. J. (2021). Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. JAMA cardiology, 6(9), 1023-1031. https://doi.org/10.1001/jamacardio.2021.1651
White, Harvey D, et al. "Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial." JAMA cardiology vol. 6,9 (2021): 1023-1031. doi: https://doi.org/10.1001/jamacardio.2021.1651
White HD, O'Brien SM, Alexander KP, Boden WE, Bangalore S, Li J, Manjunath CN, Lopez-Sendon JL, Peteiro J, Gosselin G, Berger JS, Maggioni AP, Reynolds HR, Hochman JS, Maron DJ. Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. JAMA Cardiol. 2021 Sep 01;6(9):1023-1031. doi: 10.1001/jamacardio.2021.1651. PMID: 33938917; PMCID: PMC8094032.
Copy Download .nbib Format: NLM
Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections.

Transplantation direct

Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE.
PMID: 34514117
Transplant Direct. 2021 Sep 07;7(10):e762. doi: 10.1097/TXD.0000000000001222. eCollection 2021 Oct.

Transplanting hepatitis C viremic donor organs into hepatitis C virus (HCV)-negative recipients is becoming increasingly common; however, practices for posttransplant direct-acting antiviral (DAA) treatment vary widely. Protracted insurance authorization processes for DAA therapy often lead to treatment delays.METHODS: At...

Cite
Stewart ZA, Stern J, Ali NM, et al. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct. 2021;7(10):e762doi: 10.1097/TXD.0000000000001222.
Stewart, Z. A., Stern, J., Ali, N. M., Kalia, H. S., Khalil, K., Jonchhe, S., Weldon, E. P., Dieter, R. A., Lewis, T. C., Funches, N., Crosby, S., Seow, M., Berger, J. C., Dagher, N. N., Gelb, B. E., Watkins, A. C., Moazami, N., Smith, D. E., Kon, Z. N., Chang, S. H., Reyentovich, A., Angel, L. F., Montgomery, R. A., & Lonze, B. E. (2021). Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplantation direct, 7(10), e762. https://doi.org/10.1097/TXD.0000000000001222
Stewart, Zoe A, et al. "Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections." Transplantation direct vol. 7,10 (2021): e762. doi: https://doi.org/10.1097/TXD.0000000000001222
Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct. 2021 Sep 07;7(10):e762. doi: 10.1097/TXD.0000000000001222. eCollection 2021 Oct. PMID: 34514117; PMCID: PMC8425828.
Copy Download .nbib Format: NLM
Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy.

Journal of comparative effectiveness research

Laliberté F, Ashton V, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Berger JS.
PMID: 34378989
J Comp Eff Res. 2021 Nov;10(16):1235-1250. doi: 10.2217/cer-2021-0150. Epub 2021 Aug 11.

No abstract available.

Cite
Laliberté F, Ashton V, Kharat A, et al. Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. J Comp Eff Res. 2021;10(16):1235-1250doi: 10.2217/cer-2021-0150.
Laliberté, F., Ashton, V., Kharat, A., Lejeune, D., Moore, K. T., Jung, Y., Lefebvre, P., & Berger, J. S. (2021). Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. Journal of comparative effectiveness research, 10(16), 1235-1250. https://doi.org/10.2217/cer-2021-0150
Laliberté, François, et al. "Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy." Journal of comparative effectiveness research vol. 10,16 (2021): 1235-1250. doi: https://doi.org/10.2217/cer-2021-0150
Laliberté F, Ashton V, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Berger JS. Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. J Comp Eff Res. 2021 Nov;10(16):1235-1250. doi: 10.2217/cer-2021-0150. Epub 2021 Aug 11. PMID: 34378989.
Copy Download .nbib Format: NLM
Showing 301 to 306 of 306 entries